<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03550040</url>
  </required_header>
  <id_info>
    <org_study_id>18005</org_study_id>
    <nct_id>NCT03550040</nct_id>
  </id_info>
  <brief_title>3D Versus Robot Assisted Laparoscopic Prostatectomy.</brief_title>
  <official_title>3D Versus Robot Assisted Laparoscopic Prostatectomy. A Prospective Randomized Non-inferiority Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seinajoki Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tampere University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, prospective study to compare the direct and indirect costs, functional and
      oncologic results of 3D laparoscopic and robot assisted radical prostatectomy procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The direct and indirect costs, functional and oncologic results of robot assisted radical
      prostatectomy (RALP) are compared to those of 3D laparoscopic radical prostatectomy. The
      hypothesis of the study is that the functional and oncologic results of the two operative
      methods are equal, but the direct costs of RAPL are significantly higher. A randomized,
      prospective non-inferiority study will will enroll 280 patients randomized 1:1 to both
      operative approaches to test this hypothesis. The primary functional outcome measure is the
      proportion of patients with complete urinary continence (no protective pad use) at 12 months
      post operatively. Secondary functional outcome measure is the preservation erectile function
      at 12 months post operatively. Oncologic outcome measures are the proportion of patients with
      undetectable post operative prostate specific antigen levels and positive surgical margins at
      pathological examination. The direct and indirect costs of both operative approaches are
      recorded.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective randomized study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary continence</measure>
    <time_frame>12 months</time_frame>
    <description>Expanded Prostate Cancer Index Composite (EPIC) Short Form (EPIC-26), urinary domain score is used to assess the return of continence post operatively. The percentage of patients with no protective pad use at 12 months post operatively is the main outcome measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Erectile function</measure>
    <time_frame>12 months</time_frame>
    <description>International Index of Erectile Function (IIEF-5) Questionnaire score is used to quantify the return of erectile function post operatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate specific antigen</measure>
    <time_frame>12 months</time_frame>
    <description>Post operative prostate specific antigen levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of surgical margins at pathologic examination.</measure>
    <time_frame>up to 12 months</time_frame>
    <description>The oncological outcome is evaluated by the presence of cancerous tissue at the surgical margins of the specimen at pathologic examination.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>costs of treatment</measure>
    <time_frame>12 months</time_frame>
    <description>Direct and indirect treatment related costs.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Robot assisted prostatectomy.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: radical prostatectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3D laparoscopic prostatectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: radical prostatectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical prostatectomy</intervention_name>
    <description>Surgical removal of the prostate</description>
    <arm_group_label>3D laparoscopic prostatectomy</arm_group_label>
    <arm_group_label>Robot assisted prostatectomy.</arm_group_label>
    <other_name>Total prostatectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Localized prostate cancer undergoing radical prostatectomy

          -  Patient has to understand and be able to write and read Finnish language

          -  No prior head injury, dementia or Parkinson's disease

          -  No concomitant malignant illness

          -  Life expectancy of at least 10 years

          -  35-74 years of age

        Exclusion Criteria:

          -  Locally advanced prostate cancer (T4)

          -  Suspicion or documented metastases (M1)

          -  Serum PSA &gt; 20 ng/ml

          -  Prior laparoscopic hernia surgery employing non resorbable mesh

          -  Prior pelvic irradiation or major surgery

          -  Prior malignant disease within prior 5 years excluding skin cancer (non-melanoma).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>34 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antti Kaipia, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>chief, dept of urology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antti Kaipia, M.D., Ph.D.</last_name>
    <phone>503130454</phone>
    <phone_ext>+358</phone_ext>
    <email>antti.kaipia@pshp.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jarno Riikonen, M.Dd., Ph.D.</last_name>
    <phone>408430957</phone>
    <phone_ext>+358</phone_ext>
    <email>jarno.riikonen@pshp.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antti Kaipia, M.D., Ph.D.</last_name>
      <phone>503130454</phone>
      <phone_ext>+358</phone_ext>
      <email>antti.kaipia@pshp.fi</email>
    </contact>
    <contact_backup>
      <last_name>Jarno Riikonen, M.D., Ph.D.</last_name>
      <phone>408430957</phone>
      <phone_ext>+358</phone_ext>
      <email>jarno.riikonen@pshp.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Juha Koskim√§ki, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tomi Pakarainen, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jarno Riikonen, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 14, 2018</study_first_submitted>
  <study_first_submitted_qc>June 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2018</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tampere University Hospital</investigator_affiliation>
    <investigator_full_name>Antti Kaipia</investigator_full_name>
    <investigator_title>Chief physician, department of urology</investigator_title>
  </responsible_party>
  <keyword>radical prostatectomy</keyword>
  <keyword>laparoscopic prostatectomy</keyword>
  <keyword>robot assisted prostatectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient demographic, primary and secondary outcome measures available upon request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>2020 onward for 5 years.</ipd_time_frame>
    <ipd_access_criteria>IPD will be made for relevant high quality reseach uopn request.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

